Successful Treatment with Bosentan for Pulmonary Hypertension and Reduced Peripheral Circulation in Juvenile Systemic Sclerosis

• DOI: 10.1007/s00246-011-0056-z
• Publication Date: 2011-07-25T12:34:24Z
• Authors: Masaki Shimizu; Yoko Hashida; Kazuyuki Ueno; Tadafumi Yokoyama; Yuko Nakayama; Takekatsu Saito; Kunio Ohta; Kazuhiko Takehara; Akihiro Yachie
• Keywords: Sulfonamides; Scleroderma, Systemic; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Bosentan; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Echocardiography; Thermography; Humans; Female; Vascular Resistance; Pulmonary Wedge Pressure; Child; Antihypertensive Agents; Follow-Up Studies

Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis (SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 10-15% of adult patients with SSc. The ET receptor antagonist bosentan has been shown to be effective in the treatment of adult patients with SSc-PAH. Furthermore, it has been shown that bosentan ameliorates decreased skin perfusion and digital ulceration secondary to SSc. However, the effectiveness and safety of bosentan for treatment of juvenile SSc still remains unclear. We describe a case of juvenile SSc-PAH successfully treated with bosentan. The present case shows that bosentan ameliorated PAH and peripheral circulation as evaluated by cold stress thermography. No bosentan-related adverse events such as liver dysfunction were observed. Prospective randomized trials are required to validate the effectiveness of bosentan for patients with juvenile SSc; however, bosentan might be useful for the management of patients with juvenile SSc.